Aptamer News and Research

RSS

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.

10 May 2011

Seventeen projects granted access to PRACE Research Infrastructure's Tier-0 resources

On this second PRACE regular call, a new system, CURIE funded by GENCI and installed at CEA, Bruyères-Le-Châtel, France and designed by BULL, came into production adding capability to the PRACE Research Infrastructure (RI). CURIE is the second Tier-0 system in the PRACE RI after "JUGENE" (GCS at Jülich). The number of PRACE systems will continue to grow and provide more capacity and services to the European communities.

6 Apr 2011

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

29 Mar 2011

World's first cancer stem cell-targeting chemical missile

Deakin University medical scientists have created the world's first cancer stem cell-targeting chemical missile, placing them a step closer to creating a medical 'smart bomb' that would seek out and eradicate the root of cancer cells.

18 Feb 2011

New England Biolabs adds OneTaq and OneTaq Hot Start DNA Polymerases to line of PCR reagents

New England Biolabs has expanded its line of PCR reagents to include OneTaq™ and OneTaq Hot Start DNA Polymerases. Optimized blends of Taq and Deep Vent® DNA Polymerases, these new products offer robust amplification across a wide range of templates, including routine, AT-rich and GC-rich amplicons.

From New England Biolabs 15 Feb 2011

New compound appears to prevent pain crises in sickle cell disease: GHSU

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.

1 Feb 2011

New approach to biomarker detection for early lung cancer diagnosis

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.

2 Dec 2010

Regado presents poster on REG3 at AHA Scientific Sessions meeting

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting.

18 Nov 2010

Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases

Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3.

4 Nov 2010

Researchers identify biomarkers for mesothelioma and pancreatic cancer

Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer, pancreatic and mesothelioma.

29 Sep 2010

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

3 Sep 2010

NEC, SomaLogic sign agreement to explore aptamer related businesses in life sciences, healthcare markets

NEC Corporation and privately held SomaLogic, Inc. announced today that they have signed an agreement to explore aptamer related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies.

31 Aug 2010

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

Officials at Texas Tech University System's Office of Technology Commercialization announced Wednesday (June 9) the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.

10 Jun 2010

BBSRC, EPSRC fund £1.5M for synthetic biology projects under EuroSYNBIO Programme

Four new projects, announced today, will develop biological methods that offer a new approach to antibiotic production, power generation for extremely small mechanical components, new classes of medicines and innovative techniques to study cell biology.

19 May 2010

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Regado Biosciences announces completion of Series D financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.

18 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009